A phase 3 clinical trial evaluating the efficacy of extended-release injectable risperidone for patients with schizophrenia showed a statistically significant delay in time to relapse, compared to the placebo.
The use of CYP2D6 and CYP2C19 genotyping to guide antipsychotic prescribing did not improve drug persistence in patients with schizophrenia, according to a randomized clinical trial published online in JAMA Network Open.
Take our quiz to test your knowledge of the burden and impact of schizophrenia, including the average potential life lost to the disease, co-occurring mental and behavioral health disorders, and an increased rate of suicide.
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.
Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”